News
-
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program
Onco-Innovations Limited reports progress in scale-up and development for ONC010 oncology program, focusing on A83 and B4 precursor components. Collaboration with Dalton Pharma Services aims at future GMP production -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Onco-Innovations advances CMC program by initiating analytical method validation for ONC010 API, partnering with Dalton Pharma Services for IND-enabling studies and Phase I clinical development support -
-
-
-
